Navigation Links
Mylan Selected as a Leading ARV Supplier to India's National AIDS Control Organization
Date:9/4/2012

HYDERABAD, India and PITTSBURGH, Sept. 4, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Laboratories Limited has been selected as a leading supplier of antiretroviral (ARV) drugs to India's National AIDS Control Organization (NACO). NACO is a division of India's Ministry of Health and Family Welfare and is responsible for overseeing HIV/AIDS control programs in India. NACO's objective is to halt and reverse the HIV/AIDS epidemic in India over the next five years through integrated programs for prevention, care and support and treatment. NACO manages 35 HIV Prevention and Control Societies, which implement NACO's programs at the State level and manage more than 350 ARV treatment centers.

Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's 7 billion people access to high quality medicines, and helping to ensure access to high quality, affordable ARVs is a core part of this mission. Only through access to these vital medicines can we stem the tide of HIV/AIDS in India and around the world. We are honored that Mylan has been selected as a significant supplier to NACO and look forward to helping this critical organization achieve its mission."

Approximately one-third of HIV/AIDS patients in developing countries depend on a Mylan ARV product, and Mylan has recently entered the Indian commercial market, starting with a portfolio of ARV drugs. Mylan's wide range of ARV products includes active pharmaceutical ingredients and 43 first- and second-line finished doses, nine of which are pediatric products.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
2. Mylan Launches Lithium Carbonate Extended-Release Tablets USP
3. Mylan Launches Commercial Operations in India, Starting with a Broad, Innovative Portfolio of ARV Products to Treat HIV/AIDS
4. Mylan Applauds Study Highlighting $1 Trillion in Savings for U.S. Health Care System Due to Generic Drugs Over Past Decade
5. Mylan Schedules Second Quarter 2012 Financial Results Conference Call and Live Webcast
6. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
7. Mylan Launches Thiamine Hydrochloride Injection
8. Mylan Launches Generic Version of Lipitor®
9. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
10. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
11. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , January 24, 2017 The ... of USD 3.8 billion by 2025, according to a ... growth can be attributed to the rising initiatives by ... diagnosis of micro calcifications in breast tissue. Some significant ... and Breast Cancer Organization are promoting the early diagnosis ...
(Date:1/24/2017)... 2017 Research and Markets has announced the ... Actuator - Forecast to 2025" report to their offering. ... Global Optogenetics Market ... the next decade to reach approximately $76.24 million by 2025. ... include growing count of labs using optogentic techniques for neurosciences, quick ...
(Date:1/24/2017)... The global  active pharmaceutical ingredients (API) market  is ... on a new report by Grand View Research, Inc. The rising prevalence ... market over the forecast period. Advancements in recombinant molecular technologies and high ... Continue Reading ... ...
Breaking Medicine Technology:
(Date:1/24/2017)... City, IA (PRWEB) , ... January 24, 2017 , ... ... the country, has taken great care to design a program that provides teachers with ... abroad and domestically. This online teaching certificate is ideal for post-baccalaureate students and HigherEducation.com ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... Really Need to Thrive , Well-meaning studies such as the Fordham Institute’s ... can better serve top students, such as including gifted or high-achieving students as ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the American Cancer ... good news for prostate cancer patients: incidents of cancer is down as is the ... the cancer death rate has dropped from its peak of 215.1 in 1991 to ...
(Date:1/24/2017)... ... January 24, 2017 , ... The NewKILO JRP, a ... (NMIs) and co-funded by the European Union (EU), was completed in May 2015. The ... instead being maintained and used in air, which presents some challenges to establishing traceability ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost water advocate ... Global Climate Change and Your Health on Voice America, once again welcomed one ...
Breaking Medicine News(10 mins):